FP6Excellence award2005–2008

PHARMENG · The reaction engineering of Pharmaceuticals: Efficient production of complex drug molecules

FP6 — Marie Curie Actions (Human Resources and Mobility)

Duration
2005-09-01 → 2008-08-31
EU contribution
€665,557
Participants
1
Scheme
EXC

Lines connect the coordinator with its partners.

Results in brief

Final Activity Report Summary - PHARMENG (The Reaction Engineering of Pharmaceuticals: Efficient Production of Complex Drug Molecules)

Homogeneous catalysts lack the advantages of their heterogeneous analogues, such as easy separation and catalysts' recycling, prevention of metal leaching, improvement of stability etc. The immobilisation of catalytic active compounds on solid supports is therefore a promising method for overcoming the drawbacks of homogeneous systems while maintaining their advantages. As such, the primary goal of this project was the development of covalent immobilised organometallic compounds and heterogeneous biocatalysts. The first selected catalytic system was group4 metallocenes, since these compounds were known to be highly active and selective for the synthesis of pharmaceutical intermediates. In order to optimise the new catalysts and support the synthetic approaches, molecular modelling computations were used. The following significant progresses were achieved: 1. the synthesis of various tethered Ethylenebis(indenyl) (EBI) titanocenes; 2. the covalent immobilisation of the functional metallocenes onto hydrogen-terminated silicon-particles, H-terminated Si(111) wafers and functionalised silica-gel particles; 3. the successful testing of the new homogeneous and heterogeneous metallocenes for the hydrosilylation of imines. Furthermore, we established the heterogenisation of Pd-complexes using methods analogous to those for the metallocenes. The activities of the heterogeneous Pd-catalysts were successfully tested for Buchwald-Hartwig aminations and Suzuki reactions. In addition to the immobilisation of these organometallic catalysts, we developed a versatile two-step method that allowed covalent linking of biomolecules to silicon (Si) surfaces. The first step involved the attachment of an epoxyalkene on a hydrogen (H) terminated Si-surface by ultra violet (UV) mediated hydrosilylation. In the second step, the terminal oxirane of the alkene moiety reacted with the biomolecule leading to a covalent attachment of the enzyme. Using standard photometric assays we could show that the immobilised enzyme was still active and exhibited a notable long-term stability. Regarding simulation of pharmaceutical reactors, the flow in industrial-scale equipment was studied. Such reactors included, for example, fermentation reactors up to a volume of 250 m3. In these systems the high concentration of microorganisms led to a complex flow behaviour of the broth, the so-called non-Newtonian flow behaviour, leading to challenges in reactors' scale-up and operation. We used the Lattice-Boltzmann method to effectively simulate the flow in these reactors. With this method it was for the first time possible to simulate non-Newtonian fluid flow in such equipment in non-preceded high detail. During the last project years a simulation tool was developed to effectively simulate multiphase flow. The method was able to compute flow around deforming boundaries, e.g. bubbles moving in a liquid. More significantly, the code was also able to calculate the distribution of chemical species in the liquid. Furthermore, it was possible to include chemical reactions in the computations. The simulation tool ran on parallel computers and was able to handle non-Newtonian fluid behaviour, including viscoelastic fluids. It was applied to many industry-relevant systems, e.g. catalytic hydrogenation reactions. In addition, research activities included the analysis of processes relevant for the pharmaceutical industry, such as decontamination technologies or novel technologies for the production of drugs. Therefore, we used state of the art techniques, e.g. computational fluid dynamics and computation on parallel computers. The results were useful for the improvement of these processes and provided a sound basis for the scale up of a novel extrusion device. Finally, in terms of particle technology, we used specialised simulation techniques, namely the discrete element method, as well as a sophisticated experimental setup to study mixing, granulation and drying of powders.

Data: CORDIS, © European Union

Project objective

Traditionally, empirical methods are used in the life-science industry to discover new drugs. Therapeutic effectiveness or bioavailability is determined mostly by trial and error - even today. However, rational discovery of drugs is beginning to revolutionize the industry. Unfortunately, the same cannot be said for the manufacturing of the final drug product - despite the fact that drugs are complex products, with a number of engineered features. Also, new drugs coming to the market are larger molecules, which are designed to be a complex, three-dimensional molecule to targets specific enzymes or cell surface receptors.This current trend is called the advent of the large-molecule drugs". Large-molecule drugs, however, have one setback. They are difficult to make, and often it is nearly impossible to deliver them to the body. Thus, significant scientific know-how and expertise is required to make a drug into a product, i.e., there is a compelling need to apply engineering and science principles to this industry. The proposed program of the Marie Curie Chair (MCC) addresses exactly this issue, i.e., how to make a product from a newly discovered molecule. The research program will be a unique, multi-disciplinary combination of quantum-computational chemistry, experimental chiral catalysis, molecular design, and cutting-edge computer DNS simulations of multi-phase reactive flows in pharmaceutical processes.The MCC also proposes a strong educational program combined with out-reach initiatives to disseminate his work to a broad audience, and to train young researches in a relevant and new area. This initiative lies also well within the scope of the Graz University of Technology to form a Life-Science Engineering Centre that includes areas such as advanced material s, bio-catalysis, reaction and bio-engineering, and nano-technology. In all activities the MCC will specifically address the need to foster women in science and engineering, as he has done in the past."

Original text from CORDIS.

Participants

  • GRAZ UNIVERSITY OF TECHNOLOGY · GRAZCoordinatorAustria

Links

Data: CORDIS, © European Union